Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?-Reference-Cited by-同舟云学术

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Published:2017-04 Issue: Volume:106 Page:110-114
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ou Sai-Hong Ignatius,Lee Thomas K.,Young Lauren,Fernandez-Rocha Maria Y.,Pavlick Dean,Schrock Alexa B.,Zhu Viola W.,Milliken Jeffrey,Ali Siraj M.,Gitlitz Barbara J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. Next-generation sequencing reveals a novel NSCLC ALK. F1174 V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib;Ou;J. Thorac. Oncol.,2014

2. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer;Friboulet;Cancer Discov.,2014

3. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov.,2016

4. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib;Cha;J. Thorac. Oncol.,2016

5. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib;Takegawa;Ann. Oncol.,2016

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histologic transformation of non‐small‐cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms;Cancer Science;2024-05-27

2. ALK-rearranged and EGFR wild-type lung adenocarcinoma transformed to small cell lung cancer: a case report;Frontiers in Oncology;2024-04-23

3. Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance;Chinese Medical Journal Pulmonary and Critical Care Medicine;2024-03

4. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure;Frontiers in Immunology;2024-02-06

5. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation;Journal of Experimental Medicine;2024-01-29